FDA to Assess 2026 DSCSA Implementation for Small Pharmacies Through Technology Evaluation
Assessing Electronic Tracing Capabilities of Small Pharmacies
The U.S. Food and Drug Administration (FDA) is conducting a survey to evaluate whether small dispensing pharmacies can electronically track prescription drug information in an interoperable manner, with the survey period ending on September 22, 2026. The target pharmacies are those with a total of 25 or fewer full-time pharmacists and pharmacy technicians as of November 27, 2024. The survey measures the accessibility of software and hardware, the cost of implementation and maintenance, and the ability to connect with wholesaler systems. This is not simply a data-gathering exercise but a process to establish the basis for alternative compliance methods and schedules that can be applied to entities facing significant economic burdens.
November 2026 Marks a Critical Regulatory Milestone
The Drug Supply Chain Security Act (DSCSA) was enacted on November 27, 2013, and requires manufacturers to electronically exchange transaction information and transaction statements up to the point of dispensing. The FDA has granted a temporary exemption to small dispensing pharmacies and their trading partners from certain enhanced requirements until November 27, 2026. Therefore, the period following the completion of this survey will be used to test data connectivity, exception handling, and recall/suspicious product investigation procedures in a real-world operational environment. Pharmacies that are slow to prepare may experience operational disruptions in receiving shipments and verifying available inventory after the exemption expires, and patient access may be affected by the intensity of regulatory enforcement.
The Entire Prescription Drug Distribution Network, Not Individual New Drugs, is the Focus
This initiative is not related to the approval of specific brand-name, generic, or targeted-molecule drugs, or Phase 1, 2, or 3 clinical trials. Instead, it focuses on the distribution data of DSCSA-covered prescription drugs. This is a U.S. federal law implementation measure, not an FDA, EMA, or PMDA product approval or advisory committee (AdComm) vote. According to IQVIA, U.S. prescription drug spending is projected to increase from $548 billion in 2024 to $606 billion in 2025, representing a 10.6% increase, highlighting the significant economic implications of tracking failures. The key competitive factor is not competition among standard therapies but the ability of regulatory compliance platforms, such as those based on TraceLink, LSPedia, and SAP, to connect and share serialized and tracked data based on the EPCIS standard.
The Costs and Resilience of the Top 3 Wholesalers are Being Tested
McKesson Corporation (MCK), Cencora, Inc. (COR), and Cardinal Health, Inc. (CAH) are the leading publicly traded wholesalers that must exchange electronic transaction information with pharmacies, and they are directly exposed to connection errors and customer support costs. Conversely, companies with their own portals, onboarding support, and exception management capabilities can reduce customer attrition and order cancellations among independent pharmacies. The FDA's assessment will also provide a legal basis for designing exemption application procedures or alternative implementation schedules if excessive economic burdens are demonstrated, thereby reducing the risk of a full-scale, uniform implementation. This is not a partnership involving transaction payments, upfront fees, milestone payments, royalties, or equity investments; therefore, the investment focus is on operating costs and service stability in the second half of 2026, rather than revenue generation.
The U.S. prescription drug distribution infrastructure, which accounts for $606 billion in net spending in 2025, is approaching the final milestone of the small pharmacy exemption on November 27, 2026, as mandated by the DSCSA. In the short term, McKesson (MCK), Cencora (COR), and Cardinal Health (CAH) will bear the burden of onboarding and customer support costs, as well as the risk of electronic transaction information errors, but a stable network will enhance customer retention and order continuity. For researchers and patients, the key benefit is the improved ability to quickly identify and track counterfeit or suspect products, rather than changes in clinical stage or specific target molecules. In the medium to long term, competition among TraceLink, LSPedia, and SAP-based platforms will be determined by EPCIS interoperability, exception management speed, and the total cost of ownership for small pharmacies. The outcome of the FDA survey, and whether it leads to alternative compliance methods or additional schedules, will determine the actual distribution of regulatory costs, making a 'Watchlist' approach appropriate for investment decisions.
Source: FDA Drug Approvals (rss)